Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review. - Wikidata - wikimedia - TriplyDB

Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.

Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.

http://www.wikidata.org/entity/Q38085657

about

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals.Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice.Pursuit of a perfect insulin.A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?Oral Insulin Delivery in a Physiologic Context: Review.Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart.In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study.Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.

P2860

Q33658772-293E35C2-EBBD-420B-965F-FBD86491965C Q36361469-C754043F-7BC7-491F-8F63-EA7DC0924412 Q37054947-DAB69471-A13A-486D-968C-406B8F36FE31 Q37389682-098C94C8-705F-478D-A9E0-7482CACDEE3D Q38176677-11A9CCCE-D417-4D9B-8E73-F13F12DFBB84 Q38778988-12EEBC2B-5519-406D-BD8D-B4B635C099E2 Q38970550-75CDF2A7-8AC2-4A7A-9C75-6BB79DA19C68 Q39309680-FE131552-88F4-417B-A868-20AD1969B814 Q39400642-FEC7F99E-E7AE-48E5-95FC-390E1CD99EE4 Q41558812-FC22FDA8-9EFF-4652-A92F-08F583B9B766 Q42491076-361B9E2D-790D-4730-BE46-398AF24163C6 Q46150815-A652948D-8CD8-455B-B778-6F5D00CA2525 Q47925155-2DE4BC6F-D5E1-4023-AD41-5034AE20B651 Q53449720-2FF9937C-3DDC-48A8-AC8C-3FA54397491E

P2860

Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.

http://www.wikidata.org/entity/Q38085657

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Variability of glucose-lowerin ...... sal insulin therapy: a review.

@en

type

label

Variability of glucose-lowerin ...... sal insulin therapy: a review.

@en

prefLabel

Variability of glucose-lowerin ...... sal insulin therapy: a review.

@en

P1433

Q38085657-0E19F0BD-EDD6-4DD6-8338-EE47B69FA95F

P1476

Q38085657-316258ED-B943-4FC1-9A88-1F67B63BE0D4

P2093

Q38085657-20D45A1C-29C0-467F-A74D-C07FE2D794B6

Q38085657-7FF5E7AC-FB8C-4B58-8878-DD58EF08E0A5

P2860

Q38085657-00320696-1D4E-4D41-8BC3-EE7B40AA9BD0

Q38085657-01656F18-506A-422E-91E3-9DC237E2FB21

Q38085657-0177DF37-69CB-4053-9A0A-15F20A54EA6F

Q38085657-07AE7915-E0CD-4B15-8E47-7D080CB6E58A

Q38085657-0E72973C-4FF2-4F7C-9079-60E66938B606

Q38085657-0F96466F-9E5E-4D1F-8FA5-56A6E26ACE06

Q38085657-1298F634-CEB5-4174-ACDD-9AF49FD4A403

Q38085657-147306D3-7920-4839-AAD7-358FE8C34A3C

Q38085657-14801DB2-BF39-40FD-A5AD-02F4781D1FC4

Q38085657-1CB467C9-0EE7-4BCB-A430-F71C926F2682

P304

Q38085657-D2649789-3B87-4201-B76D-6A0FD21B067A

P31

Q38085657-0B1056D8-CFE7-477B-8637-EDE1558475F9

P356

Q38085657-2DA2A6AD-6333-4FE5-8E64-3E2FACF18365

P433

Q38085657-948751E9-7757-4C62-900A-5AA1F42D4F88

P478

Q38085657-028DE888-9E84-4540-8B1C-E28A244BB379

P577

Q38085657-16656AC0-FCF2-4F1A-B0F1-2D244F4E048F

P698

Q38085657-018AFC70-8EF8-428D-8532-AD969944144A

P356

P1433

Diabetes, Obesity and Metabolism

P1476

Variability of glucose-lowerin ...... sal insulin therapy: a review.

@en

P2093

J Vora

http://www.w3.org/2001/XMLSchema#string

T Heise

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus.

Prediction of severe hypoglycemia.

Postprandial glucose regulation: new data and new implications.

In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.

Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy.

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

P304

701-712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12087

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23451796

http://www.w3.org/2001/XMLSchema#string